FibroGen has reached agreement with the FDA on important design elements for a pivotal Phase 3 clinical trial for roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic ...
Good day and welcome to the FibroGen Third Quarter 2024 Earnings Conference Call. All participants will be in listen-only mode. [Operator Instructions] Please note this event is being recorded. I ...
FibroGen Inc (NASDAQ:FGEN) shares initially traded higher Tuesday morning after the company said the FDA cleared its Investigational New Drug (IND) of FG-3165. FibroGen also announced a new clinical ...
Initiated the Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC) Reached agreement ...
FibroGen focuses on developing Pamrevlumab for pancreatic cancer therapy after disappointing trial results for other indications. If successful, Pamrevlumab’s phase 3 trials in pancreatic cancer could ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback